Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

Fosun Pharma’s HLX97 Wins NMPA Phase I Approval – First-in-Class KAT6A/B Inhibitor Targets Advanced Solid Tumors

Fineline Cube Mar 6, 2026
Company Drug

Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial

Fineline Cube Mar 6, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Earns Two BTDs for HER2+ Malignancies

Fineline Cube Sep 1, 2023

The US Food and Drug Administration (FDA) has granted AstraZeneca (AZ; NASDAQ: AZN) and Daiichi...

Company Drug

Bayer Funds Landmark Trials for Kerendia in Heart Failure Treatment Expansion

Fineline Cube Sep 1, 2023

Germany-based pharmaceutical company Bayer (ETR: BAYN) has announced funding for three investigator-sponsored collaborative studies aimed...

Company Drug

EMA and FDA Review AbbVie’s Skyrizi for Ulcerative Colitis Indication Extension

Fineline Cube Sep 1, 2023

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have accepted...

Company Drug

Shandong Buchang Pharmaceuticals’ BC001 for mCRC Accepted for Review by NMPA

Fineline Cube Aug 31, 2023

Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced that the...

Company Drug

Sirnaomics’ STP707 siRNA Drug Shows Promising Results in Phase I Solid Tumor Study

Fineline Cube Aug 31, 2023

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has revealed that all patients have been...

Company Drug

Servier Group’s Pancreatic Cancer Therapy Onivyde Launches in Major Chinese Cities

Fineline Cube Aug 31, 2023

France-based Servier has announced the first prescriptions for its pancreatic cancer therapy, Onivyde (irinotecan), in...

Company

Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus

Fineline Cube Aug 31, 2023

China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first...

Policy / Regulatory

CDE Releases 73rd Batch of Chemical Generic Reference Preparations with Updates

Fineline Cube Aug 31, 2023

The Center for Drug Evaluation (CDE) has released the 73rd batch of chemical generic reference...

Company

Lee’s Pharmaceutical Holdings Ltd Reports H1 2023 Revenue Dip Amid Product Portfolio Growth

Fineline Cube Aug 31, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its financial report for the first...

Company Deals

Watchmaker Genomics and Exact Sciences Corporation Ink Deal to Advance TAPS Technology

Fineline Cube Aug 31, 2023

US-based Watchmaker Genomics has announced a multi-year, co-exclusive agreement with compatriot firm Exact Sciences Corporation...

Company Deals

XtalPi Inc. Partners with Edelweiss Connect to Revolutionize Skincare Safety Assessment

Fineline Cube Aug 31, 2023

Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership with...

Company Deals

Takeda Secures Exclusive Rights to ImmunoGen’s Elahere in Japan Through New Agreement

Fineline Cube Aug 31, 2023

Japanese pharmaceutical company Takeda (TYO: 4502) has entered into an exclusive collaboration and license agreement...

Company

Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff

Fineline Cube Aug 31, 2023

Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for...

Company

Zhejiang Dian Diagnostics Reports 2023H1 Revenue Dip, Strategic Expansion Continues

Fineline Cube Aug 31, 2023

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has released its financial report for the...

Company Deals

Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development

Fineline Cube Aug 31, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech,...

Company Drug

Pfizer and BioNTech Receive Positive CHMP Opinion for Comirnaty Vaccine

Fineline Cube Aug 31, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Dizal Pharmaceutical’s Golidocitinib Earns Priority Review for r/r PTCL Treatment in China

Fineline Cube Aug 30, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its drug golidocitinib has been...

Company Deals

Ronovo Surgical Secures Pre-Series B+ Funding to Advance Modular Surgical Robots

Fineline Cube Aug 30, 2023

Shanghai-based minimally invasive surgical robot developer, Ronovo Surgical, has reportedly raised close to RMB 200...

Company Drug

AIM Vaccine Co., Ltd Launches Phase III Trial for 23-Valent Pneumococcal Vaccine

Fineline Cube Aug 30, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III...

Company Deals

Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies

Fineline Cube Aug 30, 2023

Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million)...

Posts pagination

1 … 445 446 447 … 631

Recent updates

  • Fosun Pharma’s HLX97 Wins NMPA Phase I Approval – First-in-Class KAT6A/B Inhibitor Targets Advanced Solid Tumors
  • Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial
  • Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration
  • HutchMed Reports $548.5 Million 2025 Revenue – FRUZAQLA Drives 26% Growth Amid China Market Headwinds
  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s HLX97 Wins NMPA Phase I Approval – First-in-Class KAT6A/B Inhibitor Targets Advanced Solid Tumors

Company Drug

Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial

Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Company

HutchMed Reports $548.5 Million 2025 Revenue – FRUZAQLA Drives 26% Growth Amid China Market Headwinds

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.